Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
| ▸ | CDA | P32320 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13501646 | 0.93 | KDM4E (0.36) | SMN1; SMN2MAPTALDH1A1KDM4ETOP2A | |
| SCHEMBL992853 | 0.86 | — | — | |
| SCHEMBL2610828 | 0.84 | SMN1; SMN2 (0.36) | SMN1; SMN2MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL10210309 | 0.83 | SMN1; SMN2 (0.35) | SMN1; SMN2MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL19402861 | 0.83 | SMN1; SMN2 (0.35) | SMN1; SMN2MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL12512979 | 0.83 | SMN1; SMN2 (0.35) | SMN1; SMN2MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL24880262 | 0.79 | SMN1; SMN2 (0.37) | SMN1; SMN2MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL18821387 | 0.79 | SMN1; SMN2 (0.32) | SMN1; SMN2MAPT | |
| SCHEMBL14390809 | 0.78 | ACE (0.42) | SMN1; SMN2MAPTALDH1A1CHRM1CDA | |
| SCHEMBL31291736 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2MAPTCHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | Bial—R&D Investments, S.A. (PT) | 2024-10-15 | — | — | US | disclosed |
| US-20230382864-A1 | PYRIDINONE MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382864-A1 | PYRIDINONE MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4249480-A1 | DIPHENYLPYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Northwest A&F University (CN) | 2023-09-27 | — | — | EP | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20080008682-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7192954-B2 | Monocyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192954-B2 | Monocyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1232166-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | Pharmasset Limited (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001034618-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | PHARMASSET LIMITED (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | SMN1; SMN2 1064/4885MAPT 2309/4885ALDH1A1 1784/4885 |
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | GBA1, GALC, GBA3 | SMN1; SMN2 90/4885MAPT 316/4885ALDH1A1 1260/4885 |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | SMN1; SMN2 3245/4885MAPT 4564/4885ALDH1A1 1402/4885 |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | SMN1; SMN2 1064/4885MAPT 2309/4885ALDH1A1 1784/4885 |
| US-20230382864-A1 | PYRIDINONE MK2 INHIBITORS AND USES THEREOF | ENPP2, PLP2, PDXK | SMN1; SMN2 2697/4885MAPT 2983/4885ALDH1A1 2928/4885 |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | SMN1; SMN2 1064/4885MAPT 2309/4885ALDH1A1 1784/4885 |
| US-20070259924-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | SMN1; SMN2 3402/4885MAPT 4551/4885ALDH1A1 911/4885 |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | SMN1; SMN2 1064/4885MAPT 2309/4885ALDH1A1 1784/4885 |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | ACE2, ACE, PNP | SMN1; SMN2 1178/4885MAPT 2507/4885ALDH1A1 579/4885 |
| US-20080008682-A1 | Modulators of toll-like receptor 7 | TLR7, TLR6, TLR3 | SMN1; SMN2 2869/4885MAPT 4446/4885ALDH1A1 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.